Tonghua Dongbao Pharmaceutical (600867.SS) Earnings Analysis
Tonghua Dongbao Pharmaceutical (600867.SS) next reports earnings on 2026-08-25, consensus EPS 0.06 CNY. Last quarter (2026-04-19) it missed with EPS 0.01 CNY vs 0.04 CNY est (-75%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 13.12.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600867.SS next report earnings?
| Next earnings date | 2026-08-25 |
|---|---|
| Consensus EPS estimate | 0.06 CNY |
| Revenue estimate | 0.81B |
600867.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-19 | 0.01 CNY | 0.04 CNY | -75% | Miss |
| 2025-08-25 | 0.05588 CNY | 0.06 CNY | -6.9% | Miss |
| 2025-04-25 | 0.06 CNY | 0.06 CNY | 0% | Beat |
| 2024-10-25 | 0.09 CNY | 0.09 CNY | 0% | Beat |
| 2024-08-16 | -0.22484 CNY | 0.13 CNY | -273% | Miss |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
600867.SS valuation and analyst view
| Trailing P/E | 13.12 |
|---|---|
| Trailing EPS | 0.58519 CNY |
| Price / book | 2.37 |
| Dividend yield | 3.69% |
| Market cap | 16.06B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Tonghua Dongbao Pharmaceutical (600867.SS)'s next earnings date?
Tonghua Dongbao Pharmaceutical is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.06 CNY and revenue estimate of 0.81B.
Did 600867.SS beat earnings last quarter?
In its 2026-04-19 report, 600867.SS posted EPS of 0.01 CNY versus a 0.04 CNY estimate — a miss of 75%.
What is 600867.SS's earnings track record?
Over the last 5 reported quarters with consensus data, 600867.SS beat estimates 2 times (40%).
What is 600867.SS's current P/E ratio and EPS?
600867.SS trades at a trailing P/E of 13.12 on trailing EPS of 0.585186237012334 CNY.
What do analysts rate 600867.SS?
600867.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.